Pete Salzmann

Pete Salzmann brings to Immunovant 20 years of experience from various leadership roles at Eli Lilly and Company, where he most recently served as Global Clinical Development Leader for baricitinib (Olumiant®). He was responsible for designing and executing comprehensive indication development strategy and overseeing clinical trial protocols of baricitinib. During his tenure at Lilly, Dr. Salzmann was instrumental in bringing a number of highly-successful drugs to market, including Taltz®, and led the global development and commercialization of products in a wide range of therapeutic categories, including immunology. Dr. Salzmann also served as General Manager and started or expanded multiple Lilly businesses in major markets around the world, including China.